The Patent Finder

Axikin Pharmaceuticals, Inc.

Also on record
Records under this name other than the patents Axikin Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 3 patents it holds.

Back to Axikin Pharmaceuticals, Inc.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,242,118Arylsulfonamide derivatives for use as CCR3 antagonists in the treatment of inflammatory and immunological disorders
Term ended
Term ended Sep 4, 2022 · USPTO record
Term endedTerm ended Sep 4, 2022USPTO record
US 7,674,7972-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders
Lapsed on the fee record
Ended Mar 9, 2022 · USPTO record
Lapsed on the fee recordEnded Mar 9, 2022USPTO record
US 8,658,642Arylsulfonamide CCR3 antagonists
Lapsed on the fee record
Ended Feb 25, 2022 · USPTO record
Lapsed on the fee recordEnded Feb 25, 2022USPTO record
US 9,637,460Isotopically enriched arylsulfonamide CCR3 antagonists
Lapsed on the fee record
Ended May 2, 2021 · USPTO record
Lapsed on the fee recordEnded May 2, 2021USPTO record
US 9,540,351Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
Lapsed on the fee record
Ended Jan 10, 2021 · USPTO record
Lapsed on the fee recordEnded Jan 10, 2021USPTO record
US 9,382,2373,5-diaminopyrazole kinase inhibitors
Lapsed on the fee record
Ended Jul 5, 2020 · USPTO record
Lapsed on the fee recordEnded Jul 5, 2020USPTO record
US 9,365,5563,5-diaminopyrazole kinase inhibitors
Lapsed on the fee record
Ended Jun 14, 2020 · USPTO record
Lapsed on the fee recordEnded Jun 14, 2020USPTO record
US 9,346,7923,5-diaminopyrazole kinase inhibitors
Lapsed on the fee record
Ended May 24, 2020 · USPTO record
Lapsed on the fee recordEnded May 24, 2020USPTO record
US 9,206,1862-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity for the treatment of inflammatory or immunological disorders
Formerly held
Lapsed on the fee record
Ended Dec 8, 2019 · USPTO record
Lapsed on the fee recordEnded Dec 8, 2019USPTO record
US 9,187,4252,5-disubstituted arylsulfonamide CCR3 antagonists
Lapsed on the fee record
Ended Nov 17, 2019 · USPTO record
Lapsed on the fee recordEnded Nov 17, 2019USPTO record
10 of 20 patents shown.
Pro members see all 20.
Pro members: see all 20 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited